[week king] DRGs has become the "arrow out of the way". Are the enterprises ready for the target? After 4 + 7, do tens of millions of medical representatives face unemployment? I don't think so!

This week's point 1 DRGs has become an "arrow out of the way" Are the enterprises ready for the target? 2 Are tens of millions of medical representatives facing unemployment? I don't think so! 3 In the third quarter, the revenue of Pianzihuang was gratifying, and the R & D investment increased by 91% year-on-year; 4 Tianshili could go to Hong Kong for listing, and "youzopiclone" was rated as the first of its kind It is important to hear that DRGs has become an "arrow out of the way" Are the enterprises ready for the target? On October 23, the National Medical Security Bureau issued the notice on printing and distributing the technical specifications and grouping scheme of DRG paid national pilot (hereinafter referred to as the notice) At the same time, the national medical security DRG grouping and payment technical specifications (hereinafter referred to as the technical specifications) and the national medical security DRG (chs-drg) grouping scheme (hereinafter referred to as the grouping scheme) were officially released Looking back on May this year, the state health insurance bureau released a list of 30 pilot cities for DRG payment, and planned to work in accordance with the three-year three-step promotion strategy of "top-level design, simulation operation and actual payment" In this reform, the National Health Insurance Bureau has integrated many versions, taking everyone's advantages, making up for everyone's shortcomings, forming an authoritative grouping scheme, and forming a consensus national version But at the same time, because of the uneven development, wide distribution, regional differences and other reasons of the economic and medical level of each pilot area in China, during the implementation of DRG, each area is allowed to make changes according to its own situation, give certain independent authority to the local area, and formulate its own DRGs according to the city's own data, provided that the main direction cannot be changed During the turbulent period of medicine, there were 4 + 7 volume purchase before and DRGs pilot after If 4 + 7 is just a simple price for volume, to reduce the high gross profit of enterprises, so as to achieve a sharp drop in drug price, DRGs is to change medical behavior, reduce the proportion of irrational drugs, maximize the use of drugs, and put an end to medical waste In order to achieve the sustainable reduction of medical insurance cost, we should enhance the value of drug products Of course, everything can't be accomplished overnight, but the arrow of departure has been aimed at the bull's-eye Major pharmaceutical enterprises need to make good use of the policy implementation "dead time", so as to have a thorough understanding of market changes in time, actively respond to them, and make clear the long, medium and short-term plans of the company Among them, R & D innovation has undoubtedly become the primary factor for enterprises to consider Chemical medicine has been developed all over the world Only Chinese people can make efforts for it! On the 25 day of the National Conference on Chinese medicine held in Beijing, Sun Chunlan, member of the Political Bureau of the CPC Central Committee and vice premier of the State Council, attended the meeting and delivered speeches, conveying the important instructions of general secretary Xi Jinping and Premier Li Keqiang on Chinese medicine: to follow the law of development of traditional Chinese medicine, to inherit the essence, to keep up with innovation, to accelerate the modernization and industrialization of Chinese medicine, and to promote the emphasis of both Chinese and Western medicine Traditional Chinese medicine and Western medicine complement and coordinate each other's development, promote the high-quality development of the cause and industry of traditional Chinese medicine, promote the development of traditional Chinese medicine to the world, give full play to the unique advantages and functions of traditional Chinese medicine in disease prevention and treatment, and contribute to the construction of a healthy China and the realization of the Chinese dream of the great rejuvenation of the Chinese nation To carry forward TCM culture, we need to vigorously promote the cultivation of TCM talents, scientific and technological innovation and drug research and development, and promote the implementation of the opinions on promoting the inheritance, innovation and development of TCM Vice Premier sun Chunlan also stressed that: next, strengthening and improving the service system, encouraging social forces to run medical institutions such as traditional Chinese medicine clinics, reforming institutions and teacher education, and improving the level of clinical diagnosis and treatment become the primary goal At the same time, we also need to actively explore folk medicine, build genuine medicine base, and strengthen quality supervision We will deepen the reform of medical insurance, price, examination and approval, promote scientific and technological innovation, open exchanges, and promote the high-quality development of traditional Chinese medicine It can be seen that although the development of traditional Chinese medicine is much more arduous than chemical medicine and innovative medicine, the strong are always lonely The development of traditional Chinese medicine is destined to have a different road from others Only the Chinese people can make efforts on this road, and we can't be discouraged by the development of traditional Chinese medicine We need to constantly explore the unique advantages of traditional Chinese medicine treatment and connect with the world, so we can Can carry it forward to the world Day will be down to Si Ren, Chinese medicine entrepreneurs you can be ready? After the industry's hot news of 4 + 7, do tens of millions of medical representatives face unemployment? I don't think so! The 4 + 7 expansion makes the pharmaceutical representatives of major pharmaceutical enterprises nervous The dissolution of the medical team and sales team of the winning 4 + 7 product, Plavix, by Sanofi, a multinational pharmaceutical company, has exacerbated the mood of the representatives Now the matter has a follow-up: the media has revealed the preferential scheme for Sanofi to negotiate and terminate the corresponding consultation of employees According to the plan, the economic compensation is calculated according to the average wage of the first 12 months before the end of August 2019, and the additional compensation is the basic wage of N + 3 months As of November 30 of this year, the social security accumulation fund and commercial insurance are available for employees to apply for other positions in the business department There is no doubt that this is more true In fact, since the end of "4 + 7" expansion bidding and procurement, similar things are often said by people Not only Sanofi, but Beijing Jialin Pharmaceutical Co., Ltd., one of the 4 + 7 bid winning enterprises, recently announced the dissolution of the national sales team Before the end of the month, employees left Of course, the answer is different from person to person, but it is clear at present, because it is not only Sanofi and Jialin pharmaceutical, since the "4 + 7" expansion bidding and procurement is over, the motivation for domestic enterprises, whether winning or not, to build a large-scale sales team is gone So if you lose your job, it will be more difficult to find another one So the question is, does this mean that once the 4 + 7 policy fully dominates the pharmaceutical market, will most of the pharmaceutical representatives lose their jobs? In my opinion, although it does have an impact to some extent, it can't be ignored that the responsibility of pharmaceutical representatives is not only to sell drugs, but also to guide doctors to use drugs correctly and maximize the use of drugs Perhaps, the overall leadership of 4 + 7 will promote the standardization, professionalization and specialization of pharmaceutical representative industry Jokingly, "after this, The pharmaceutical representative is not qualified for the master of clinical medicine.. "On October 22, Sichuan Provincial Drug Administration released the sixth drug quality announcement in 2019 According to the requirements of the drug sampling plan of Sichuan Province in 2019, the drug supervision and administration departments of all cities (prefectures) have carried out sampling inspection on drug production, operation and use units The spot check found that 23 batches of drugs did not meet the requirements, including 5 batches of preparations, namely Jiangtangning capsule, dabudu capsule, Xiaoyan Lidan tablet, Nujin pill, Fuzi Lizhong pill; 18 batches of decoction pieces, including fresh white skin, cicada exuviate, vinegar myrrh, epimedium, Qianhu, etc According to the announcement, the relevant drug supervision and administration departments have investigated and dealt with the above-mentioned non-conforming drugs in accordance with laws and regulations, and require the relevant enterprises to suspend the sale and use of the products, recall the products, carry out the investigation on the causes of non-conforming drugs, and earnestly carry out in-depth rectification Enterprise information Tianshili can go to Hong Kong for listing, "youzopiclone" has become the first of its kind on October 22, Tianshili Pharmaceutical Group Co., Ltd issued a notice, and China Securities Regulatory Commission approved its holding subsidiary Tianshili bio to issue no more than 415 million overseas listed foreign shares, with a par value of 1 yuan per share, all of which are common shares Upon completion of this offering, TSL bio will be listed on the main board of the Hong Kong stock exchange The next day, Tianshili announced that Jiangsu Diyi, a wholly-owned subsidiary, had received the supplementary approval for drugs (approval No.: 2019b03973) of 3mg specification of youzopiclone tablet (trade name "Wenfei") issued by the State Food and drug administration, which was the first drug in China to pass the conformity evaluation of generic drugs As if speaking to the world of their own development prospects Indeed, at present, there are 13 research projects in the research of Tianshili biology, including 3 projects of cardiovascular and cerebrovascular diseases, 6 projects of tumor and autoimmune diseases, and 4 projects of digestive and metabolic diseases Among them, there are two core varieties, puyouke and anmeimu monoclonal antibody The performance of listed products is relatively stable This time, there are new first generic drugs of the same kind, which can be described as a stable and competitive enterprise It is feasible to focus on pioneering drugs without losing the market But in the current market scene where there are many innovative drug research projects, how to improve the R & D speed is Tianshili, which needs to be planned next In the third quarter, the revenue of pianzehuang was gratifying, and the R & D investment increased by 91% year on year On October 24, Zhangzhou Pianzihuang Pharmaceutical Co., Ltd (600436 SH) issued the third quarter report In the first three quarters, the company achieved an operating revenue of 4.342 billion yuan, a year-on-year increase of 21.07%; the net profit attributable to the parent company was 1.109 billion yuan, a year-on-year increase of 20.56%; the operating revenue in the third quarter was 1.447 billion yuan, a year-on-year increase of 22.44%; the net profit attributable to the parent company was 363 million yuan, a year-on-year increase of 19.87% It is worth noting that in 2019, the R & D investment of pianzehuang increased significantly, which was clearly stated in the announcement that "the increase of R & D cost is mainly due to the increase of R & D investment of the parent company" Compared with 2018, the average growth rate of R & D investment of pianzehuang in 2019 is nearly 90% In today's era when innovative drugs are becoming a trend, traditional enterprises must not lag behind with others at this time, nor just talk about "innovation" verbally, but also actively become practitioners of "innovation", especially in (drug) technological innovation, we should always spare no effort and forge ahead In the first three quarters, Hengrui's revenue was nearly 17 billion yuan, and its sales expenses soared In the evening of October 24, Hengrui pharmaceutical released its third quarter report, which showed that in the first three quarters of this year, Hengrui pharmaceutical realized revenue of 16.945 billion yuan, a year-on-year increase of 36.01%; and net profit of 3.735 billion yuan, a year-on-year increase of 28.26% Revenue or profit, the growth rate of which has increased significantly compared with last year The reason why Hengrui has such good benefits in the first three quarters is that the continuous listing of five products has supported its performance growth, among which the PD-1 variety of carrellizumab (trade name: Alito) has been affirmed by some securities companies since its listing, but its specific sales information still needs to wait for the release of Hengrui pharmaceutical's 2019 annual report at the beginning of next year However, in this report, it is worth noting that the sales expenses of Hengrui medicine reached 2.512 billion yuan, an increase of nearly 700 million yuan compared with 1.84 billion yuan in the same period last year In fact, in the past five years, the sales expenses of Hengrui medicine accounted for nearly 40% of the revenue Combined with the inspection list of 77 pharmaceutical enterprises, Hengrui medicine was also listed There are concerns that Hengrui's growing sales costs may be a concern However, from the overall data of pharmaceutical enterprises, we can find that the larger the enterprises are, the higher the sales expenditure will be This is related to our national conditions The CSRC only inspects the high sales expenditure caused by illegal behaviors As long as the sales expenditure of enterprises is reasonable and legal, there is absolutely no problem Penicillin information source: Sina pharmaceutical, eight point Jianwen, yiou, pharmaceutical representative, pharmaceutical geography, cyberblue, Xinkangjie, etc statement: this point of view only represents the author, does not represent the position of yaozhiwang, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the article